Detailed description page of Hmrbase2

This page displays user query in tabular form.

11330 details
Primary information
ID11330
Uniprot IDP01275
DescriptionGlucagon precursor [Cleaved into- - Glicentin; Glicentin-related polypeptide(GRPP); Oxyntomodulin (OXY) (OXM); Glucagon; Glucagon-like peptide 1(GLP-1); Glucagon-like peptide 1(7-37) (GLP-1(7-37)); Glucagon-likepeptide 1(7-36) (GLP-1(7-36)); Glucagon-like peptide 2 (GLP-2)].
OrganismHomo sapiens
TxonomyEukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata (jawed vertebrates); Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Boreoeutheria; Euarchontoglires; Primates; Haplorrhini; Simiiformes; Catarrhini; Hominoidea (apes); Hominidae (great apes); Homininae; Homo; Homo sapiens (Human)
Subcellular LocationSecreted
Developmental StageNA
SimilarityBelongs to the glucagon family.
Tissue SpecificityGlucagon is secreted in the A cells of the islets of Langerhans. GLP-1; GLP-2; oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP1 and GLP2
Post Translational ModificationProglucagon is posttranslationally processed in a tissue- specific manner in pancreatic A cells and intestinal L cells. In pancreatic A cells; the major bioactive hormone is glucagon cleaved by PCSK2/
FunctionOxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension; which may contribute to satiety by causing a sensation of fullness
Length180
Molecular Weight20909
NameOxyntomodulin
SequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA
Sequence map37 (53-89)
PDB ID1BH01D0R1NAU
DrugpediaNA
ReceptorP43220; O95838; P43220; P47871;P47871
DomainNA
Pharmaceutical UseAvailable under the names Glucagon (Eli Lilly) and GlucaGen or Glucagon Novo Nordisk (Novo Nordisk). Used to treat severe hypoglycemia in insulin-dependent diabetics.